News
APMD
19.27
+1.69%
0.32
Weekly Report: what happened at APMD last week (1019-1023)?
Weekly Report · 1d ago
Weekly Report: what happened at APMD last week (1012-1016)?
Weekly Report · 10/19 10:34
Bank of America Securities Remains a Buy on Apnimed, Inc. (APMD)
TipRanks · 10/12 12:45
Weekly Report: what happened at APMD last week (1005-1009)?
Weekly Report · 10/12 10:41
Bank of America Puts These 2 Under-the-Radar IPO Stocks on Its Buy List
TipRanks · 10/06 09:58
Weekly Report: what happened at APMD last week (0928-1002)?
Weekly Report · 10/05 10:40
Weekly Report: what happened at APMD last week (0921-0925)?
Weekly Report · 09/28 10:34
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 09/21 17:06
Weekly Report: what happened at APMD last week (0914-0918)?
Weekly Report · 09/21 10:34
Weekly Report: what happened at APMD last week (0907-0911)?
Weekly Report · 09/14 10:40
Apnimed: What We Know Heading Into The Feb PDUFA
Seeking Alpha · 09/10 12:40
Apnimed: Buy Rating Reiterated on Strong Oxnimbi OSA Profile and Unchanged $50 Price Target
TipRanks · 09/09 13:15
Apnimed Swings To Q2 Profit, Eyes February 2027 FDA Decision On AD109 In Obstructive Sleep Apnea
NASDAQ · 09/09 09:33
Apnimed, Inc. reports Q2 results
Seeking Alpha · 09/08 20:41
Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M
Benzinga · 09/08 20:41
*Apnimed 2Q Net $125.9M >APMD
Dow Jones · 09/08 20:40
Press Release: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 09/08 20:39
Press Release: Apnimed Reports Second Quarter -2-
Dow Jones · 09/08 20:39
Weekly Report: what happened at APMD last week (0831-0904)?
Weekly Report · 09/07 10:32
Weekly Report: what happened at APMD last week (0824-0828)?
Weekly Report · 08/31 10:41
More
Webull provides a variety of real-time APMD stock news. You can receive the latest news about Apnimed through multiple platforms. This information may help you make smarter investment decisions.
About APMD
Apnimed, Inc. is a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. The Company's clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.